RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
Abstract Previous studies have shown the clinical benefit of rechallenging the RAF pathway in melanoma patients previously treated with BRAF inhibitors. 44 patients with multiple tumors harboring RAF alterations were rechallenged with a second RAF inhibitor, either as monotherapy or in combination with other therapies, after prior therapy with a first RAF inhibitor. This retrospective observational study results showed that rechallenging with RAFi(s) led to an overall response rate of 18.1% [PR in thyroid (1 anaplastic; 3 papillary), 1 ovarian, 2 melanoma, 1 cholangiocarcinoma, and 1 anaplastic astrocytoma]. The clinical benefit rate was 54.5%; more than 30% of patients had durable responses with PR and SD lasting > 6 months. The median progression-free survival on therapy with second RAF inhibitor in the rechallenge setting either as monotherapy or combination was shorter at 2.7 months (0.9-30.1 m) compared to 8.6 months (6.5-11.5 m) with RAF-1i. However, the median PFS with RAF-2i responders (PFS-2) improved at 12.8 months compared to 11.4 months with RAF-1i responders. The median OS from retreatment with RAF-2i was 15.5 months (11.1-30.8 m). Further prospective studies are needed to validate these results and expand targeted therapy options for RAF-aberrant cancers..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Molecular cancer - 23(2024), 1 vom: 26. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nelson, Blessie Elizabeth [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
BRAF inhibitors |
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12943-024-01982-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055309798 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055309798 | ||
| 003 | DE-627 | ||
| 005 | 20240327065053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12943-024-01982-4 |2 doi | |
| 035 | |a (DE-627)SPR055309798 | ||
| 035 | |a (SPR)s12943-024-01982-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |a 570 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Nelson, Blessie Elizabeth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Abstract Previous studies have shown the clinical benefit of rechallenging the RAF pathway in melanoma patients previously treated with BRAF inhibitors. 44 patients with multiple tumors harboring RAF alterations were rechallenged with a second RAF inhibitor, either as monotherapy or in combination with other therapies, after prior therapy with a first RAF inhibitor. This retrospective observational study results showed that rechallenging with RAFi(s) led to an overall response rate of 18.1% [PR in thyroid (1 anaplastic; 3 papillary), 1 ovarian, 2 melanoma, 1 cholangiocarcinoma, and 1 anaplastic astrocytoma]. The clinical benefit rate was 54.5%; more than 30% of patients had durable responses with PR and SD lasting > 6 months. The median progression-free survival on therapy with second RAF inhibitor in the rechallenge setting either as monotherapy or combination was shorter at 2.7 months (0.9-30.1 m) compared to 8.6 months (6.5-11.5 m) with RAF-1i. However, the median PFS with RAF-2i responders (PFS-2) improved at 12.8 months compared to 11.4 months with RAF-1i responders. The median OS from retreatment with RAF-2i was 15.5 months (11.1-30.8 m). Further prospective studies are needed to validate these results and expand targeted therapy options for RAF-aberrant cancers. | ||
| 650 | 4 | |a Rechallenge |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a RAF pathway |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a BRAF inhibitors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a BRAF-altered solid tumors |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Roszik, Jason |4 aut | |
| 700 | 1 | |a Ahmed, Jibran |4 aut | |
| 700 | 1 | |a Barretto, Carmelia Maria Noia |4 aut | |
| 700 | 1 | |a Nardo, Mirella |4 aut | |
| 700 | 1 | |a Campbell, Erick |4 aut | |
| 700 | 1 | |a Johnson, Amber M |4 aut | |
| 700 | 1 | |a Piha-Paul, Sarina A. |4 aut | |
| 700 | 1 | |a Oliva, Isabella C. Glitza |4 aut | |
| 700 | 1 | |a Weathers, Shiao-Pei |4 aut | |
| 700 | 1 | |a Cabanillas, Maria |4 aut | |
| 700 | 1 | |a Javle, Milind |4 aut | |
| 700 | 1 | |a Meric-Bernstam, Funda |4 aut | |
| 700 | 1 | |a Subbiah, Vivek |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular cancer |d BioMed Central, 2002 |g 23(2024), 1 vom: 26. März |w (DE-627)SPR028851633 |w (DE-600)2091373-4 |x 1476-4598 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g number:1 |g day:26 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12943-024-01982-4 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |e 1 |b 26 |c 03 | ||